Literature DB >> 26335396

CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele.

Andrea Gaedigk1, Amanda K Riffel2, J Steven Leeder3.   

Abstract

Cytochrome P450 (CYP) 2D6, a major contributor to the metabolism and bioactivation of many clinically used drugs, is encoded by a complex, highly polymorphic gene locus. To aid in the characterization of CYP2D6 allelic variation, we developed allele-specific long-range PCR (ASXL-PCR) to amplify only the allele of interest for further characterization by PCR. This development was achieved utilizing single-nucleotide polymorphisms in the upstream region of CYP2D6 and a universal CYP2D6-specific reverse primer. This approach was assessed and optimized on samples with known genotypes. The application of ASXL-PCR clarified a case with a complex genotype (CYP2D6*2x2/*4N+*4) by amplifying the duplicated gene units separately for subsequent analysis. Furthermore, ASXL-PCR and subsequent sequence analysis also resolved genotype discord in a mother/daughter relationship by revealing the presence of the CYP2D6*59 allelic variant in both individuals. Finally, we demonstrated that the 2939G>A single-nucleotide polymorphism present on CYP2D6*59 interfered with the TaqMan genotype assay that detected 2850C>T, causing false genotype assignments. Assay interference was resolved using an alternative TaqMan genotype assay currently available as a custom-made assay. These examples demonstrate the utility of ASXL-PCR for improved CYP2D6 allele/haplotype characterization. This fast, easy-to-perform method is not limited to CYP2D6 but can be adapted to any gene locus for which polymorphic sites are known.
Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26335396      PMCID: PMC4630174          DOI: 10.1016/j.jmoldx.2015.06.007

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  30 in total

1.  Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects.

Authors:  Andrea Gaedigk; Liliane Ndjountché; Roger Gaedigk; J Steven Leeder; L DiAnne Bradford
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

2.  Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations.

Authors:  Andrea Gaedigk; Maria Isidoro-García; Robin E Pearce; Santiago Sánchez; Virginia García-Solaesa; Carolina Lorenzo-Romo; Gloria Gonzalez-Tejera; Susan Corey
Journal:  Eur J Clin Pharmacol       Date:  2010-05-16       Impact factor: 2.953

3.  CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.

Authors:  Andrea Gaedigk; L Dianne Bradford; Sarah W Alander; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2006-01-13       Impact factor: 3.922

4.  Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual.

Authors:  Andrea Gaedigk; Dorothee Frank; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-09-17       Impact factor: 2.953

5.  The effect of primer-template mismatches on the detection and quantification of nucleic acids using the 5' nuclease assay.

Authors:  Ralph Stadhouders; Suzan D Pas; Jeer Anber; Jolanda Voermans; Ted H M Mes; Martin Schutten
Journal:  J Mol Diagn       Date:  2009-11-30       Impact factor: 5.568

Review 6.  Complexities of CYP2D6 gene analysis and interpretation.

Authors:  Andrea Gaedigk
Journal:  Int Rev Psychiatry       Date:  2013-10

7.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

9.  Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants.

Authors:  Andrea Gaedigk; Lazara Karelia Montane Jaime; Joseph S Bertino; Anick Bérard; Victoria M Pratt; L Dianne Bradfordand; J Steven Leeder
Journal:  Front Pharmacol       Date:  2010-10-04       Impact factor: 5.810

10.  SNP genotyping using TaqMan technology: the CYP2D6*17 assay conundrum.

Authors:  Andrea Gaedigk; Natalie Freeman; Toinette Hartshorne; Amanda K Riffel; David Irwin; Jeffrey R Bishop; Mark A Stein; Jeffrey H Newcorn; Lazara Karelia Montané Jaime; Mariana Cherner; J Steven Leeder
Journal:  Sci Rep       Date:  2015-03-19       Impact factor: 4.379

View more
  23 in total

1.  Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection.

Authors:  Wanqiong Qiao; Suparna Martis; Geetu Mendiratta; Lisong Shi; Mariana R Botton; Yao Yang; Andrea Gaedigk; Raymon Vijzelaar; Lisa Edelmann; Ruth Kornreich; Robert J Desnick; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2018-12-06       Impact factor: 2.533

Review 2.  Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.

Authors:  Yao Yang; Mariana R Botton; Erick R Scott; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

3.  CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels.

Authors:  Balmiki Ray; Eren Ozcagli; Wolfgang Sadee; Danxin Wang
Journal:  Pharmacogenet Genomics       Date:  2019-02       Impact factor: 2.089

4.  The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity.

Authors:  Jean C Dinh; Erin C Boone; Vincent S Staggs; Robin E Pearce; Wendy Y Wang; Roger Gaedigk; James Steven Leeder; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-11-30       Impact factor: 6.875

5.  Rare Variants in RPPH1 Real-Time Quantitative PCR Control Assay Binding Sites Result in Incorrect Copy Number Calls.

Authors:  Robert J Sicko; Paul A Romitti; Marilyn L Browne; Lawrence C Brody; Colleen F Stevens; James L Mills; Michele Caggana; Denise M Kay
Journal:  J Mol Diagn       Date:  2021-10-15       Impact factor: 5.568

Review 6.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

7.  Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population.

Authors:  Koya Fukunaga; Eiji Hishinuma; Masahiro Hiratsuka; Ken Kato; Takuji Okusaka; Takeo Saito; Masashi Ikeda; Teruhiko Yoshida; Hitoshi Zembutsu; Nakao Iwata; Taisei Mushiroda
Journal:  J Hum Genet       Date:  2020-08-05       Impact factor: 3.172

8.  Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.

Authors:  Wanqiong Qiao; Yao Yang; Robert Sebra; Geetu Mendiratta; Andrea Gaedigk; Robert J Desnick; Stuart A Scott
Journal:  Hum Mutat       Date:  2015-12-18       Impact factor: 4.878

9.  Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization.

Authors:  Amy J Turner; Praful Aggarwal; Erin C Boone; Cyrine-Eliana Haidar; Mary V Relling; Ashley D Derezinski; Ulrich Broeckel; Andrea Gaedigk
Journal:  J Mol Diagn       Date:  2021-02-22       Impact factor: 5.568

Review 10.  Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Andrea Gaedigk; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; R H N van Schaik; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2021-06-10       Impact factor: 5.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.